Other
CN
EU
USA
Description: Serdemetan (formerly JNJ26854165; JNJ-26854165; JNJ 26854165), originally developed as an activator of p53, is now considered to be a novel, potent and orally bioactive antagonist of Human Double Minute-2 (HDM-2) ubiquitin ligase with antitumor activities. It also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.
Reference: Pediatr Blood Cancer. 2012 Aug;59(2):329-32.
Product Catalog 2023
Guide to Product Handling
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Purity ≥98%
COA
MSDS
NMR